-
公开(公告)号：US09688695B2
公开(公告)日：2017-06-27
申请号：US14396771
申请日：2013-04-24
Applicant: BRISTOL-MYERS SQUIBB COMPANY , Universite De Montreal
Inventor： Jacques Banville , Roger Rémillard , Edward H. Ruediger , Daniel H. Deon , Marc Gagnon , Laurence Dubé , Julia Guy , Eldon Scott Priestley , Shoshana L. Posy , Brad D. Maxwell , Pancras C. Wong , R. Michael Lawrence , Michael M. Miller
IPC: C07D513/04 , C07D487/04 , C07D519/00 , A61K45/06 , A61K31/433 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/5025 , A61K31/5377 , A61K31/541 , A61K31/553
CPC classification number: C07D513/04 , A61K31/433 , A61K31/435 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/5025 , A61K31/5377 , A61K31/5386 , A61K31/541 , A61K31/55 , A61K31/553 , A61K45/06 , A61K51/0453 , C07B59/002 , C07B2200/05 , C07D487/04 , C07D519/00
Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
-
22.发明授权Imidazothiadiazole and imidazopyridazine derivatives as protease activated receptor 4 (PAR4) inhibitors for treating platelet aggregation 有权咪唑并噻二唑和咪唑并哒嗪衍生物作为治疗血小板聚集的蛋白酶活化受体4（PAR4）抑制剂公开(公告)号：US09518064B2
公开(公告)日：2016-12-13
申请号：US14396831
申请日：2013-04-24
Applicant: BRISTOL-MYERS SQUIBB COMPANY , Universite De Montreal
Inventor： Alain Martel , François Tremblay , Anne Marinier , Eldon Scott Priestley , Shoshana L. Posy , R. Michael Lawrence , Michael M. Miller
IPC: C07D513/04 , C07D487/04 , A61K38/12 , A61K31/433 , A61K31/437 , A61K31/4439 , A61K31/497 , A61K31/506 , A61K31/513 , A61K31/5377
CPC classification number: C07D513/04 , A61K31/433 , A61K31/437 , A61K31/4439 , A61K31/497 , A61K31/506 , A61K31/513 , A61K31/5377 , A61K38/12 , C07D487/04
Abstract: The present invention provides imidazothiadiazole compounds of Formula (I); Wherein W, Y, R0, R2, R4, Ra, Rb, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
-
公开(公告)号：US20160355507A1
公开(公告)日：2016-12-08
申请号：US15171276
申请日：2016-06-02
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： James A. Johnson , Soong-Hoon Kim , R. Michael Lawrence , Michael C. Myers , Hannguang J. Chao , Monique Phillips , Ji Jiang
IPC: C07D413/04 , C07D417/14 , C07D498/04 , C07D413/14
CPC classification number: C07D413/04 , C07D401/04 , C07D413/14 , C07D417/14 , C07D498/04
Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.
Abstract translation: 其中所有变量如说明书中所定义，以及包含任何这些新化合物的组合物。 这些化合物是可用作药物的APJ激动剂。
-
24.发明申请IMIDAZOTHIADIAZOLE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION 有权作为用于治疗细胞聚集的蛋白激活受体4（PAR4）抑制剂的咪唑唑二酮衍生物公开(公告)号：US20150133446A1
公开(公告)日：2015-05-14
申请号：US14396807
申请日：2013-04-24
Applicant: BRISTOL-MYERS SQUIBB COMPANY , Universite De Montreal
Inventor： R. Michael Lawrence , Michael M. Miller , Dietmar Alfred Seiffert , Shoshana L. Posy , Pancras C. Wong , Jacques Banville , Edward H. Ruediger , Daniel H. Deon , Alain Martel , François Tremblay , Julia Guy , Jean-François Lavallée , Marc Gagnon
IPC: C07D513/04 , A61K31/506 , A61K31/5377 , A61K31/4355 , A61K31/433 , A61K31/4439
CPC classification number: C07D513/04 , A61K31/433 , A61K31/4355 , A61K31/4439 , A61K31/506 , A61K31/5377 , A61K45/06 , C07D519/00
Abstract: The present invention provides imidazothiadiazole compounds of Formula (I) wherein A, B, D, Rx, R1, R2, R3, X1, X2 and s are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments.
Abstract translation: 本发明提供式（I）的咪唑并噻二唑化合物，其中A，B，D，Rx，R1，R2，R3，X1，X2和s如本文所定义，或其立体异构体，互变异构体，药学上可接受的盐或溶剂化物形式， 其中所有变量如本文所定义。 这些化合物是血小板聚集的抑制剂，因此可以用作药物。
-
25.发明申请IMIDAZOTHIADIAZOLE AND IMIDAZOPYRIDAZINE DERIVATIVES AS PROTEASE ACTIVATED RECEPTOR 4 (PAR4) INHIBITORS FOR TREATING PLATELET AGGREGATION 有权作为用于治疗血小板聚集的蛋白激活受体4（PAR4）抑制剂的咪唑并噻唑和咪唑吡嗪衍生物公开(公告)号：US20150119390A1
公开(公告)日：2015-04-30
申请号：US14396831
申请日：2013-04-24
Applicant: BRISTOL-MYERS SQUIBB COMPANY , Universite De Monteal
Inventor： Alain Martel , François Tremblay , Anne Marinier , Eldon Scott Priestley , Shoshana L. Posy , R. Michael Lawrence , Michael M. Miller
IPC: C07D513/04 , A61K31/433 , A61K31/5377 , A61K31/513 , A61K31/437 , A61K31/497 , A61K31/506 , A61K31/4439
CPC classification number: C07D513/04 , A61K31/433 , A61K31/437 , A61K31/4439 , A61K31/497 , A61K31/506 , A61K31/513 , A61K31/5377 , A61K38/12 , C07D487/04
Abstract: The present invention provides imidazothiadiazole compounds of Formula (I); Wherein W, Y, R0, R2, R4, Ra, Rb, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
Abstract translation: 本发明提供式（I）的咪唑并噻二唑化合物; 其中W，Y，R0，R2，R4，Ra，Rb，X1，X2，X3和X4如本文所定义，或其立体异构体，互变异构体，药学上可接受的盐，前药酯或溶剂化物形式，其中所有变量 如本文所定义。 这些化合物是血小板聚集的抑制剂，因此可以用作治疗或预防血栓栓塞障碍的药物。
-
Patent Agency Ranking
26.发明申请公开(公告)号：US20140213588A1
公开(公告)日：2014-07-31
申请号：US14346747
申请日：2012-09-26
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Lynn Abell , Leonard Adam , Cullen L. Cavallaro , Heather Finlay , Todd J. Friends , Jon J. Hangeland , Ji Jiang , R. Michael Lawrence , Jennifer X. Qiao , Carol Hui Hu , Tammy C. Wang
IPC: C07D417/06 , C07D417/04 , C07D409/04 , C07D413/06 , C07D405/06 , C07D233/61 , C07D401/06 , C07D207/277 , C07D405/04
CPC classification number: C07D207/277 , C07D207/28 , C07D207/38 , C07D233/61 , C07D401/06 , C07D401/12 , C07D403/12 , C07D405/04 , C07D405/06 , C07D409/04 , C07D413/06 , C07D417/04 , C07D417/06
Abstract: The present invention provides compounds of Formula (I): as defined in the specification and compositions comprising any of such novel compounds. These compounds are endothelial lipase inhibitors which may be used as medicaments. The disclosure also provides a novel method of treating diseases or conditions related to the activity of endothelial lipase by use of compounds according to Formula (II): as defined in the specification and compositions comprising any of the compounds.
Abstract translation: 本发明提供式（I）化合物：如说明书中所定义和包含任何这些新化合物的组合物。 这些化合物是可用作药物的内皮脂肪酶抑制剂。 本公开还提供了一种通过使用根据式（II）的化合物来治疗与内皮脂肪酶活性相关的疾病或病症的新方法：如说明书中所定义和包含任何化合物的组合物。
-
27.发明申请公开(公告)号：US20200231547A1
公开(公告)日：2020-07-23
申请号：US16639145
申请日：2018-08-16
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Shun Su , Hannguang J. Chao , Adam James Clarke , R. Michael Lawrence
IPC: C07D235/16 , C07D413/12 , C07D413/10 , C07D471/04 , C07D491/056 , C07D473/00 , C07D235/18
Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification. The compounds are apelin and APJ agonists for treating cardiovascular diseases. Preferred compounds are 2-(1,1′-biphe-1H-benzo[d]imidazole derivatives. The invention further provides compositions comprising the compounds and the compounds for use in methods of medical treatment.
-
公开(公告)号：US10590113B2
公开(公告)日：2020-03-17
申请号：US16122975
申请日：2018-09-06
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Zulan Pi , Donna M. Bilder , Robert Paul Brigance , Heather Finlay , Wen Jiang , James A. Johnson , R. Michael Lawrence , Wei Meng , Michael C. Myers , Monique Phillips , George O. Tora , Xiaojun Zhang
IPC: A61K31/505 , C07D403/06 , C07D401/06 , C07D403/14 , C07D239/557 , C07D239/54 , C07D239/545 , C07D401/14 , C07D403/02 , C07D417/14 , C07D471/04
Abstract: The present invention provides compounds of Formula (I): wherein all variables are as defined in the specification, and compositions comprising any of such novel compounds. These compounds are APJ agonists which may be used as medicaments.
-
公开(公告)号：US20190314346A1
公开(公告)日：2019-10-17
申请号：US16445913
申请日：2019-06-19
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Huji Turdi , Jon J. Hangeland , R. Michael Lawrence , Saleem Ahmad , Wei Meng , Robert Paul Brigance , Pratik Devasthale , Guohua Zhao
IPC: A61K31/438 , C07F9/59 , C07D401/10 , C07D401/14 , A61K31/5377 , C07D413/14 , C07D221/20 , C07D413/04 , A61K31/4439 , C07D401/04 , A61K31/4418 , C07D211/90 , A61K31/675 , C07D405/14 , C07F9/40 , C07F9/535 , C07D211/86 , C07D417/14 , C07D417/04 , C07D413/12 , C07D407/14 , C07D401/12 , A61K45/06
Abstract: The present invention provides compounds of Formula (I): or a stereoisomer, or a pharmaceutically acceptable salt thereof, wherein all of the variables are as defined herein. These compounds are monoacylglycerol acyltransferase type 2 (MGAT2) inhibitors which may be used as medicaments.
-
公开(公告)号：US10428077B2
公开(公告)日：2019-10-01
申请号：US16020043
申请日：2018-06-27
Applicant: BRISTOL-MYERS SQUIBB COMPANY , UNIVERSITE DE MONTREAL
Inventor： Jacques Banville , Roger Remillard , Edward H. Ruediger , Daniel H. Deon , Marc Gagnon , Laurence Dube , Julia Guy , Eldon Scott Priestley , Shoshana L. Posy , Brad D. Maxwell , Pancras C. Wong , R. Michael Lawrence , Michael M. Miller
IPC: C07D487/04 , C07D513/04 , C07D519/00 , A61K45/06 , A61K31/433 , A61K31/4439 , A61K31/454 , A61K31/496 , A61K31/497 , A61K31/5025 , A61K31/5377 , A61K31/541 , A61K31/553 , A61K31/435 , A61K31/5386 , A61K31/55 , A61K51/04 , C07B59/00
Abstract: The present invention provides thiazole compounds of Formula I wherein W, Y, R0, R2, R4, R5, R6, R7, X1, X2, X3 and X4 are as defined herein, or a stereoisomer, tautomer, pharmaceutically acceptable salt, prodrug ester or solvate form thereof, wherein all of the variables are as defined herein. These compounds are inhibitors of platelet aggregation and thus can be used as medicaments for treating or preventing thromboembolic disorders.
-
-
-
-
-
-
-
-
-
Search Results
64
records
(took 0.058 seconds)
